What’s New… Sept 11, 2024 meeting

• rifAXImin 550 mg tab
• caspofungin 50 & 70 mg IV
• DAPTOmycin 500 mg IV
  MONOGRAPHS
• LTC Nirmatrelvir + Ritonavir (Paxlovid) for Oral Treatment of COVID19 in Adults Standard Orders
• Emergency Department Adult Clinical Decision Tool (Nurse may implement) Standard Orders

• rifAXImin PO has been added to the formulary with restrictions as per Part 3 EDS criteria for reducing the risk of overt encephalopathy recurrence
• Caspofungin IV has been added to the formulary with restrictions; it requires a consultation with Adult ID Consult Service for invasive candidiasis
• DAPTOmycin IV has also been added to the formulary with restrictions; it also requires a consultation with the Adult Infectious Diseases Service for indications listed on the formulary updated on the StaffNET
• LTC Nirmatrelvir + Ritonavir (Paxlovid) for Oral Treatment of COVID-19 in Adults Standard Orders has been updated with changes due to the inclusion of off-label Paxlovid dosing for eGFR less than 30 mL/min in the updated Shared Health clinical guidance
• Emergency Department Adult Clinical Decision Tool (Nurse may Implement) Standard Orders is a revised standard order where users should apply CTAS and clinical judgement following the Clinical Decision Tool policy CLI.5110.PL.002. In PCH, we will follow the Manitoba Biosimilar Guideline Manitoba Biosimilars Initiative | Health | Province of Manitoba (gov.mb.ca). A new prescription from the prescriber is required for the products listed in the guideline
• Obstetric pre-printed MARs were recently updated to reflect the layout of the BDM cMARs.

For more info. go to the GENERAL shared folder to review the completed Pharmacy & Therapeutics minutes

Drug Monographs